- ACCRU SC-1601 EVE Trial
A randomized phase III trial studying the best dose of apixaban and how well it works in preventing secondary cancer related blood clots in cancer patients who have completed anticoagulation therapy.
A study in men with biochemically recurrent prostate cancer and PSA doubling time = 9 months at the time of study entry.
This study looks at the risks and benefits of active surveillance (AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low risk DCIS.
- AFT-28 “CANVAS”
A study to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- ALCHEMIST A081105 E4512 A151216
The ALCHEMIST trials are testing therapies that target two types of genetic changes that are thought to drive lung cancer growth: mutations in the EGFR gene and a rearrangement of the ALK gene.
- Alliance A011401
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence).
- Alliance A011502
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy.
- Alliance A021502
This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair.
- Alliance A021703 "SOLARIS"
This Alliance phase III trial looks at how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body.
- Alliance A031501
A trial studying how well pembrolizumab works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes.